<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178437</url>
  </required_header>
  <id_info>
    <org_study_id>cMPsE01</org_study_id>
    <nct_id>NCT01178437</nct_id>
  </id_info>
  <brief_title>Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy</brief_title>
  <official_title>Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy - a Prospective Pilot Study Regarding Safety, Effectiveness and Clinical Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>cerbomed GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>cerbomed GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to prove the feasibility and safety of transcutaneous, electrical
      stimulation of the vagus nerve in patients with difficult-to-treat forms of epilepsy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of performance</measure>
    <time_frame>9 months</time_frame>
    <description>rated by investigator
QOLIE-89 MADRS CCTE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's subjective assessment of epileptic shocks</measure>
    <time_frame>9 months</time_frame>
    <description>rated by patient. Subjective assessment of epileptic shocks and cognitive functions. Measured with &quot;Erlanger Kognitionstest&quot; (EKT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Further assessment of performance</measure>
    <time_frame>9 months</time_frame>
    <description>EEG long-term monitoring, MR spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Safety</measure>
    <time_frame>9 months</time_frame>
    <description>Registration of (S)AEs and drop outs</description>
  </secondary_outcome>
  <enrollment type="Actual">7</enrollment>
  <condition>Epilepsy</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>T-VNS® Stimulator cM02 (Transcutaneous Stimulation of the Vagus Nerve)</intervention_name>
    <description>daily, transcutaneous, electrical stimulation of the vagus nerve by the t-VNS device for a period of 9 months</description>
    <other_name>T-VNS® Stimulator cM02</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written Informed Consent

          -  Patients of both gender, aged from 18-75 years

          -  Diagnosis of epilepsy according to the diagnosis criteria of the DSM IV/ ICD 10
             (especially G 40.1 /G 40.2/ G 40.3)

          -  Insufficient response to at least one attempt of treatment in medical history with
             anticonvulsive medication, dosed sufficiently long and high

          -  Antiepileptic Drugs (AED) therapy must be stable at a level that promises long-term
             continuity for at least 10 before study start and has to be continued for at least 3
             months during treatment phase

        Exclusion Criteria:

          -  Absence of Informed Consent

          -  Pregnancy

          -  Psychiatric diseases, especially post-traumatic stress disorder, obsessive-compulsive
             disorders, schizophrenia, Borderline personality disorders (BPD), character disorders
             as well as major depressive disorders, anxiety disorders and eating disorders as
             comorbidity.

          -  Abuse of drugs and alcohol until 12 weeks before study start

          -  Cerebrovascular diseases

          -  Dementia

          -  Severe traumatic brain injury in medical history including invasive and non-invasive
             methods of therapy (tumor surgery, &quot;Gamma Knife Surgery&quot;)

          -  Indications of structural impairment of the basal ganglia or the brain stem

          -  active implants (e.g. cochlea implants, VNS, pacemaker)

          -  Severe neurological diseases (e.g. Morbus Parkinson, systemic neurologic diseases

          -  severe internistic diseases (e.g. arterial hypertension, respiratory failure)

          -  Bronchial asthma

          -  malignant diseases of any kind, within five years before study start

          -  Severe active infectious diseases (e.g. HIV, hepatitis)

          -  Bone diseases (e.g. Morbus Paget, recent fractures)

          -  Diseases of the ENT body system: Hearing loss of the left ear which is treated with a
             hearing instrument, all dermatologic and infectious diseases which affect the area
             around the pinna and the ear canal, severe malformation of the pinna

          -  Vagotomy

          -  Concurrent participation in other studies

          -  Other circumstances that in the opinion of the investigator might be an obstacle for
             enrolling the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Herrmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Erlangen-Nürnberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Epilepsiezentrum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2010</study_first_submitted>
  <study_first_submitted_qc>August 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <last_update_submitted>March 7, 2011</last_update_submitted>
  <last_update_submitted_qc>March 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>cerbomed GmbH</organization>
  </responsible_party>
  <keyword>seizure disorder,</keyword>
  <keyword>seizures,</keyword>
  <keyword>convulsions,</keyword>
  <keyword>grand mal,</keyword>
  <keyword>petit mal,</keyword>
  <keyword>absence seizures,</keyword>
  <keyword>repeated seizures,</keyword>
  <keyword>children's seizures,</keyword>
  <keyword>secondary epilepsy,</keyword>
  <keyword>symptomatic epilepsy,</keyword>
  <keyword>generalized seizures,</keyword>
  <keyword>partial seizure,</keyword>
  <keyword>focal seizure,</keyword>
  <keyword>partial complex seizure,</keyword>
  <keyword>anticonvulsant medication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

